Marina Caskey is an Infectious Disease physician. ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
525 E 68th St
Room A-421
New York, NY 100214870
Telephone
212-746-6320Registry record last updated 29 Apr 2016.
Clinical trials
- HepB mAb19 in Individuals With Chronic Hepatitis B Infection
Sponsor: Rockefeller University
- 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
Sponsor: Rockefeller University
- Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20255 payments
- ViiV Healthcare CompanyProgram year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor100%Emtricitabine-Tenofovir Disop100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- REACH: Research Enterprise to Advance a Cure for HIV
Weill Medical Coll of Cornell Univ
FY2026$5,414,805UM1AI164565 - INSPIRE: Innovative Strategies for Personalized Immunotherapies and Reservoir Eradication
Weill Medical Coll of Cornell Univ
FY2026$2,915,052UM1AI191237 - Defining the mechanisms of HIV resistance to bNAbs in humans
Rockefeller University
FY2026$1,569,774U01AI169385
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”